Clinical trials
Hypertrophic Cardiomyopathy (HCM) clinical trials
Below are recruiting hypertrophic cardiomyopathy (hcm) clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06433050RecruitingEarly Phase 1
Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05100420Recruiting
HCM registry and DNA/imaging data collection study
This study collects health records, heart ultrasound (echo), MRI images, and optional DNA testing for people with hypertrophic cardiomyopathy (HCM). It aims to build a large database to better understand HCM and support future research and care.
Edmonton, AlbertaAges Any age - NCT04848506Enrolling by invitationPhase 2/Phase 3
Long-term safety follow-up with aficamten for adults with HCM
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
Birmingham, AlabamaAges 18–85 - NCT02413450Enrolling by invitation
Using patient DNA cells to study inherited heart rhythm risks
This study uses your blood or genetic information to make “iPS cells,” lab-grown cells that can help researchers study inherited heart rhythm problems like LQTS, Brugada syndrome, CPVT, or early repolarization syndrome. It may help improve understanding of why these rhythms happen and guide future treatments.
Baltimore, MarylandAges 18–85 - NCT01091480Recruiting
French heart ultrasound study for hypertrophic cardiomyopathy
This is an observational study (it mainly tracks what happens over time) for people with thickened heart muscle due to hypertrophic cardiomyopathy. You may be eligible if an echocardiogram (heart ultrasound) shows the required thickness and you don’t have certain heart valve disease.
ParisAges 15 years+ - NCT07367724RecruitingPhase 2
Ademetionine for obstructive hypertrophic cardiomyopathy
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
BeijingAges 18 years+ - NCT07150299Recruiting
How heart medications affect blood flow in hypertrophic cardiomyopathy
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
ViennaAges 18 years+ - NCT06368518Recruiting
Study of hypertrophic cardiomyopathy in Austria
This study tracks people with hypertrophic cardiomyopathy, a heart muscle disease, to learn more about the condition and improve care. It does not test a new treatment but collects health information over time.
Linz, LinzAges 18 years+ - NCT04189822Enrolling by invitation
Heart rhythm genetic registry and blood sample bio bank
This study is building a Canadian database and tissue/blood bank for people and families with inherited heart rhythm conditions (and some inherited heart muscle diseases). It collects consented health and genetic information to help researchers better understand who is at risk and how these conditions work.
Vancouver, British ColumbiaAges Any age - NCT02696135Recruiting
Study of Chinese people with hypertrophic cardiomyopathy
This study looks at people with hypertrophic cardiomyopathy (HCM), a heart condition that causes part of the heart muscle to thicken for no clear reason. It will compare how HCM is identified and studied, which may help doctors better understand and manage the condition in Chinese patients.
Beijing, Beijing MunicipalityAges Any age - NCT07361289Recruiting
Mavacamten for obstructive hypertrophic cardiomyopathy in China
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07541833Recruiting
Mavacamten Treatment Patterns in Obstructive Heart Thickening
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Minato-ku, TokyoAges 18 years+ - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
La Jolla, CaliforniaAges 18 years+ - NCT07054073Recruiting
HCMR Re-Imaging: MRI follow-up for HCM patients
This study uses MRI scans to re-examine people with hypertrophic cardiomyopathy (a thickening of the heart muscle) who were part of the original HCMR study. It compares different types of HCM to learn more over time.
Boston, MassachusettsAges 18–65 - NCT07464132RecruitingPhase 1/Phase 2
New PET scan for detecting certain diseases
This trial uses a special PET scan tracer to see if it can help find and monitor diseases linked to a protein called FAP. It is for both cancer patients needing a biopsy and healthy volunteers.
Beijing, Beijing MunicipalityAges 18–85 - NCT05836259RecruitingPhase 1/Phase 2
TN-201 for heart symptoms from MYBPC3 heart disease
This early trial tests TN-201 to see how safe it is and how well it works to reduce symptoms in adults with MYBPC3-related hypertrophic cardiomyopathy. It’s designed to learn safe dosing, and you may be eligible if you have specific genetic heart changes and ongoing symptoms.
La Jolla, CaliforniaAges 18–75 - NCT07120776Recruiting
PET scan study for chest pain in hypertrophic cardiomyopathy
This trial uses a special PET scan to see if the drug Mavacamten (Camzyos) helps improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM) who have chest pain or shortness of breath. If you already take Mavacamten as part of your usual care, the study will compare your PET scan results before and after treatment.
ManchesterAges 18 years+
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hypertrophic cardiomyopathy (hcm)?
- Yes. Clin2 currently lists 42 recruiting hypertrophic cardiomyopathy (hcm) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hypertrophic cardiomyopathy (hcm) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hypertrophic cardiomyopathy (hcm) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.